Rockwell seeks FDA nod for Triferic in CKD
This article was originally published in Scrip
Executive Summary
Rockwell Medical was among the biotechs riding the rough Wall Street rails on 24 March, with its stock taking an 8.6% dive, despite submitting a new drug application (NDA) to the FDA for the company's iron replacement therapy Triferic (soluble ferric pyrophosphate citrate).